Login to Your Account



Good Phase III Data Spur NDA Expectations for Tarsa, Unigene

By Becky Jungbauer


Friday, March 25, 2011
Shares for Unigene Laboratories Inc. jumped as it announced, with partner Tarsa Therapeutics Inc., positive top-line data from their Phase III postmenopausal osteoporosis study.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription